glp 1 agonist history Timeline of GLP-1 discovery and clinical development. (a) Key events in GLP-1 Agonists - What is

1 Diabetes-related neurodegenerative disease (ND) is of particular importance due to the cognitive impairment it causes in older patients with type 2 diabetes

Max is 4.5 mg weekly

Recently, several efforts have been focused on the development of ML models for peptide 21,22 and small-molecule 23,24 design, demonstrating the success of these approaches in de novo prediction of functional molecules

Hadjyanni et al

[DOI] [PMC free article] [PubMed] [Google Scholar] 48.Du Y., Su T., Song X., Gao J., Zou D., Zuo C., Xie W., Wang B., Zhang Z., Xu J., et al

Notably, although gallbladder disorders frequently manifest, advanced gastrointestinal complications such as intestinal obstruction and periprocedural aspiration, and emergent concerns regarding suicidality and ocular problems require further longitudinal studies to refine the usage guidelines for GLP-1 RAs in susceptible populations